MDX-1206

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameMDX-1206

Drug Alias NameMDX-1435 - alkylating agent conjugate (Medarex)anti-CD19 antibody drug conjugates (Medarex/BMS)MDX-1206

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionB-lymphocyte antigen CD19 inhibitors

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMedarex Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMedarex Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A